In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
Danish biotech MinervaX, a privately held firm working on a novel, prophylactic vaccine against Group B Streptococcus (GBS), has raised $57 million from a range of new and existing sources of finance. 11 October 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk saw its shares rise 3.7% to 673.90 kroner today, on positive news announced to the stock exchange late on Tuesday. 11 October 2023
Biotechnology
Shares in San Diego-based inflammatory diseases specialist Ventyx Biosciences closed 26% lower after Tuesday’s trading. 11 October 2023
Biotechnology
With the aim of advancing its fibrosis-focused pipeline, Belgian biotech Agomab Therapeutics today announced the closing of a $100 million (94.9 million euros) Series C financing. 11 October 2023
Biosimilars
Samsung Bioepis, a business of South Korea-based Samsung BioLogics has outlined data it is presenting at the ongoing congress of the European Academy of Dermatology and Venereology (EADV). 11 October 2023
Pharmaceutical
Small molecule drugs are carving a significant niche in lung cancer treatment, an area in which AstraZeneca achieved a landmark approval from the US Food and Drug Administration (FDA) following the results of the Phase III AURA trial. 11 October 2023
Biotechnology
BioMap today announced a ground-breaking strategic collaboration with French pharma major Sanofi to co-develop cutting-edge artificial intelligence (AI) modules for biologic therapies leveraging BioMap’s AI platform. 11 October 2023
Pharmaceutical
Lifera, a biopharmaceutical company wholly-owned by the Saudi Arabian Public Investment Fund (PIF), says it has successfully completed its acquisition of a 70% stake in SaudiBio. 11 October 2023
Biotechnology
Experienced neuroscience drug development executive Robert Lenz has joined Neumora Therapeutics. 10 October 2023
Biotechnology
Johnson & Johnson’s Janssen subsidiary has submitted a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new indication for Rybrevant (amivantamab). 10 October 2023
Pharmaceutical
In the USA, the National Institutes of Health has outlined significant new investments to support research into amyotrophic lateral sclerosis (ALS). 10 October 2023
Biotechnology
US clinical-stage biotech Akero Therapeutics saw its shares slump 59% to $48.44, after it released new data Phase IIb data on its lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to non-alcoholic steatohepatitis (NASH), joining a string of companies failing in their attempts in this therapy area. 10 October 2023
Biotechnology
San Diego, USA-based biotech AnaptysBio saw its shares edge up 3.6% to $19.95, after it released results from the Phase III GEMINI-1 trial evaluating the safety and efficacy of imsidolimab (interleukin (IL)-36R MAb) in patients with generalized pustular psoriasis (GPP) flares. 10 October 2023
Pharmaceutical
Dutch biosynthetic pharma products specialist Centrient Pharmaceuticals is to open its new innovation lab at Spanish dermatology company Almirall’s R&D center in Barcelona. 10 October 2023
Pharmaceutical
Welcome to The Pharma Letter Podcast for a promotional episode, sponsored by Janssen, where we will deep dive into barriers and challenges in treating major depressive disorder (MDD), and finish with a few reasons for optimism. 10 October 2023
Biotechnology
UK antibody-drug conjugate (ADC) company Pheon Therapeutics today announced the appointment of Dr Arvin Yang as chief medical officer. 10 October 2023
Pharmaceutical
German life sciences and pharma firm Merck KGaA today announced the presentation of new analyses from the Mavenclad (cladribine) MAGNIFY-MS study. 10 October 2023
Biotechnology
Swiss pharma giant Roche has announced positive top-line long-term results from the global Phase III BALATON and COMINO studies, evaluating extended treatment intervals with Vabysmo (faricimab) in macular edema due to branch and central retinal vein occlusion. 10 October 2023
Biotechnology
USA-based immunotherapy specialist SAB Biotherapeutics has raised $130 million in a private share placement. 10 October 2023
Pharmaceutical
The US Congressional Budget Office (CBO) is on the lookout for new research that would enhance its analysis of policies affecting the use of obesity treatments - especially research on the use of anti-obesity medications (AOMs). 10 October 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze